Altis Biosystems was founded to address the biopharmaceutical industry's intense need for more accurate drug screening methods using in vitro platforms, which can more closely replicate human biology. Altis developed its intestinal platform to be the next generation for in vitro testing during drug development, allowing scientists to develop safe and more effective drugs using normal human intestinal tissue, and reducing the time and cost of drug discovery.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/11/20 | $3,100,000 | Seed |
Atlanta Technology Angels Central Texas Angel Network Hatteras Venture Partners RTP Capital VentureSouth  | undisclosed |
